4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with pioglitazone in 2 studies
| Studies (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide) | Trials (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide) | Recent Studies (post-2010) (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 62 | 0 | 14 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mutoh, M; Niho, N; Wakabayashi, K | 1 |
| Habu, S; Kusunoki, M; Miyata, T; Mori, Y; Morishita, M; Nakamura, A; Nakamura, T; Nakaya, Y; Sato, D; Tsutsumi, K; Yonemoto, T | 1 |
1 review(s) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and pioglitazone
| Article | Year |
|---|---|
Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
Topics: Age Factors; Animals; Benzamides; Bezafibrate; Cyclooxygenase 2; Genes, APC; Humans; Hyperlipidemias; Intestinal Polyps; Lipoprotein Lipase; Membrane Proteins; Mice; Organophosphorus Compounds; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
1 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and pioglitazone
| Article | Year |
|---|---|
Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.
Topics: Abdominal Fat; Adiponectin; Animals; Benzamides; Blood Glucose; Body Weight; Drug Combinations; Eating; Enzyme Activation; Hypoglycemic Agents; Insulin; Leptin; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2011 |